Milrinone
- Atc Codes:C01CE02
- CAS Codes:78415-72-2
- PHARMGKB ID:78415-72-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Corotrop; Belgium: Corotrope; Czech Republic: Corotrop; France: Corotrope; Germany: Corotrop; Greece: Corotrope; Hungary: Corotrope; Luxembourg: Corotrope; Malta: Primacor; Netherlands: Corotrope, Milrinon; Poland: Corotrope; Portugal: Corotrope; Romania: Corotrope; Slovakia: Corotrope; Spain: Corotrope; Sweden: Corotrop; UK: Primacor.
North America
Canada: Milrinone; USA: Milrinone, Primacor.
Latin America
Argentina: Corotrope; Brazil: Primacor; Mexico: Primacor.
Asia
Japan: Milrila, Milrinone.
Drug combinations
Chemistry
Milrinone: C~12~H~9~N~3~O. Mw: 211.22. (1) [3,4′-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo-; (2) 1,6-Dihydro-2-methyl-6-oxo[3,4′-bipyridine]-5-carbonitrile. CAS-78415-72-2 (1983).
Pharmacologic Category
Cardiotonic Agents; Phosphodiesterase Enzyme Inhibitor. (ATC-Code: C01CE02).
Mechanism of action
Selective phosphodiesterase inhibitor in cardiac and vascular tissue, resulting in vasodilation and inotropic effects with little chronotropic activity.
Therapeutic use
Short-term intravenous therapy of acutely-decompensated heart failure.
Pregnancy and lactiation implications
Use with caution during pregnancy or lactation.
Unlabeled use
Inotropic therapy for patients unresponsive to other acute heart failure therapies (e.g. dobutamine). Outpatient inotropic therapy for heart transplant candidates. Palliation of symptoms in end-stage heart failure patients who are not transplant candidates.
Contraindications
Hypersensitivity to milrinone, inamrinone, or any component of the formulation. Concurrent use of inamrinone.
Warnings and precautions
Arrhythmias possible; might persist even after discontinuation of therapy, especially in renal dysfunction. Hepatic effects might occur (elevations in LFTs or clinical symptoms of hepatotoxicity). Hypotension might be prolonged, especially in renal dysfunction. Electrolyte imbalances (hypokalemia or hypomagnesemia), should be corrected. Not recommended in acute myocardial infarction treatment. Use with caution in renal impairment (hypotension might be prolonged). Long-term therapy strongly discouraged.